Review
Oncology
Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra
Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.
Review
Oncology
Oscar Molina, Maria Alba Abad, Francesc Sole, Pablo Menendez
Summary: Aneuploidy, characterized by the gain or loss of chromosomes in a cell, is a hallmark of cancer. While it is more common in solid tumors, it also plays a significant role in patients with B cell acute lymphoblastic leukemia (B-ALL). Research has shown that aneuploidy promotes tumor progression.
Article
Biochemistry & Molecular Biology
Rafaela G. A. Costa, Suellen L. R. Silva, Ingrid R. S. B. Dias, Maiara de S. Oliveira, Ana Carolina B. da C. Rodrigues, Rosane B. Dias, Daniel P. Bezerra
Summary: Acute myeloid leukemia (AML) is a heterogeneous disease group with various mutations triggering malignant proliferation. AML relapse is mainly caused by leukemic stem cells (LSCs) with self-renewal capacity and resistance to traditional therapies. LSCs have low oxidative stress levels due to low mitochondrial activity and high ROS-removing pathway activity. Targeting oxidative stress could be a potential strategy to eliminate AML LSCs.
Article
Cell Biology
Aleksandra Georgievski, Anais Michel, Charles Thomas, Zandile Mlamla, Jean-Paul Pais de Barros, Stephanie Lemaire-Ewing, Carmen Garrido, Ronan Quere
Summary: This study demonstrates that extracellular vesicles (EVs) produced by proliferative acute lymphoblastic leukemia (ALL) cells can specifically target hematopoietic stem and progenitor cells (HSPC), influencing their quiescence and maintenance. The researchers discovered that ALL EVs are enriched in cholesterol and other metabolites that promote mitochondrial function in targeted HSPC. These findings provide insights into a new oncogenic mechanism and its impact on a healthy hematopoiesis system during leukemia development.
CELL DEATH & DISEASE
(2022)
Review
Medicine, General & Internal
Robin Foa, Sabina Chiaretti
Summary: Current frontline therapy for Ph-positive acute lymphoblastic leukemia, which includes tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has significantly improved survival and achieved high-level clearance of measurable tumor cells.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Anastasia M. M. Hughes, Vincent Kuek, Joyce Oommen, Grace-Alyssa Chua, Maria van Loenhout, Sebastien Malinge, Rishi S. S. Kotecha, Laurence C. C. Cheung
Summary: Components of the bone marrow microenvironment (BMM) play a significant role in the development, progression, and treatment response of acute lymphoblastic leukemia (B-ALL). This study investigated the cellular and transcriptome profiles of mesenchymal stem cells (MSCs) isolated from the BMM of an immunocompetent BCR-ABL1(+) model of B-ALL. The findings showed that leukemia-associated MSCs had reduced self-renewal capacity, upregulation of inflammatory signaling pathways, and downregulation of genes involved in extracellular matrix organization and osteoblastogenesis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Cell Biology
Vivian Morris, Dahai Wang, Zhiheng Li, William Marion, Travis Hughes, Patricia Sousa, Taku Harada, Shannan Ho Sui, Sergey Naumenko, Jeremie Kalfon, Prerana Sensharma, Marcelo Falchetti, Renan Vinicius da Silva, Tito Candelli, Pauline Schneider, Thanasis Margaritis, Frank C. P. Holstege, Yana Pikman, Marian Harris, Ronald W. Stam, Stuart H. Orkin, Angela N. Koehler, Alex K. Shalek, Trista E. North, Maxim Pimkin, George Q. Daley, Edroaldo Lummertz da Rocha, R. Grant Rowe
Summary: This study investigates LICs in MLL-rearranged B-ALL using single-cell transcriptomics and quantitative xenotransplantation. Compared to AML, MLL-r B-ALL has abundant engraftable LICs that can replenish leukemic cellular diversity. Inhibiting oxidative phosphorylation promotes LIC emergence, while inhibiting hypoxia and glycolysis impairs MLL-r B-ALL LICs.
Review
Immunology
Mohammad Hassan Hodroj, Iman Abou Dalle, Nour Moukalled, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi
Summary: The outcome of B-cell acute lymphoblastic leukemia has improved with multi-agent chemotherapy and immunotherapeutic agents. However, relapse post-transplant is still common. This review discusses strategies such as tyrosine kinase inhibitors, innovative agents, and cellular therapy to prevent and overcome relapse post allo-HCT in ALL patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Natalia-Del Pilar Vanegas, Paola Fernanda Ruiz-Aparicio, Gloria Ines Uribe, Adriana Linares-Ballesteros, Jean-Paul Vernot
Summary: The study compared the changes in MSC from B-ALL patients with those in an in vitro leukemic niche, finding that both exhibited features of a senescence process that was reversible, impacting biological and clinical significance depending on cell interactions in the bone marrow at different stages of disease progression in B-ALL.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Geoffrey Brown
Summary: The hematopoietic cell system is a complex ecosystem that can meet the needs of mature blood cells in both steady-state and emergency situations. It is highly integrated and social, adapting to different demands by generating cells biased towards specific lineages. Leukemia stem cells disrupt the cell hierarchy, being restricted to one lineage and able to alter the bone marrow stromal niches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Jing Zhou, Xing Chen, Pan Zhou, Xiaolu Sun, Yangpeng Chen, Mengke Li, Yajing Chu, Jianfeng Zhou, Xuelian Hu, Yi Luo, Weiping Yuan, Gaoxiang Wang
Summary: This study reveals the crucial role of osteopontin (OPN) in acute myeloid leukemia (AML), showing that OPN contributes to the maintenance of leukemia stem cells (LSCs) by preventing apoptosis and cell cycle arrest. Therefore, OPN could be a potential therapeutic target for AML treatment.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Yu Wei Zhang, Katharina Schoenberger, Nina Cabezas-Wallscheid
Summary: Significant progress has been made in understanding the relationship between cellular metabolism and epigenetic regulation in hematopoietic stem cells. Environmental factors, dietary habits, and hematological diseases can alter the metabolism and epigenetic features of HSCs. Understanding these mechanisms can lead to the discovery of new therapeutic targets for eliminating leukemia stem cells while preserving healthy HSCs.
Article
Hematology
Cedric S. Tremblay, Jesslyn Saw, Jacqueline A. Boyle, Katharina Haigh, Veronique Litalien, Hannah McCalmont, Kathryn Evans, Richard B. Lock, Stephen M. Jane, Jody J. Haigh, David J. Curtis
Summary: Interleukin-7 (IL-7) is important for the growth and resistance to chemotherapy of T-cell acute lymphoblastic leukemia (T-ALL), especially the early T-cell precursor subtype (ETP-ALL). Signal transducer and activator of transcription (STAT5) is universally activated in ETP-ALL and plays a crucial role in its development. Inhibition of STAT5 is necessary to block the supportive signals provided by IL-7 and eradicate leukemia stem cells (LSCs).
Article
Biochemistry & Molecular Biology
Antonella Mancusi, Francesco Zorutti, Loredana Ruggeri, Samanta Bonato, Sara Tricarico, Tiziana Zei, Roberta Iacucci Ostini, Valerio Viglione, Rebecca Sembenico, Sofia Sciabolacci, Valeria Cardinali, Massimo Fabrizio Martelli, Cristina Mecucci, Alessandra Carotti, Maria Paola Martelli, Andrea Velardi, Antonio Pierini
Summary: This study demonstrates the feasibility of using blinatumomab and DLI to treat relapses after Treg/Tcon haploidentical HSCT, and suggests that their preemptive use could improve efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Cuiyan Zhou, Fengmei Zheng, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: Previous studies have shown that TP53 mutation is associated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). However, a new study suggests that TP53 mutation may not impact survival in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
INTERNATIONAL JOURNAL OF CANCER
(2023)
Meeting Abstract
Oncology
Sonia C. Dolfi, Daniel J. Medina, Shridar Ganesan, Alexei Vazquez, Kim M. Hirshfield
Article
Oncology
Rajeev K. Boregowda, Daniel J. Medina, Elke Markert, Michael A. Bryan, Wenjin Chen, Suzie Chen, Anna Rabkin, Michael J. Vido, Samuel I. Gunderson, Marina Chekmareva, David J. Foran, Ahmed Lasfar, James S. Goydos, Karine A. Cohen-Solal
Article
Oncology
Sonia C. Dolfi, Daniel J. Medina, Aparna Kareddula, Bhavna Paratala, Ashley Rose, Jatinder Dhami, Suzie Chen, Shridar Ganesan, Gillian Mackay, Alexei Vazquez, Kim M. Hirshfield
Article
Biochemistry & Molecular Biology
Yi Ting, Daniel J. Medina, Roger K. Strair, Dale G. Schaar
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2010)
Article
Biophysics
T. Budak-Alpdogan, G. Jeganathan, K-C Lee, Z. R. Mrowiec, D. J. Medina, D. Todd, D. Moore, J. R. Bertino, R. Strair
BONE MARROW TRANSPLANTATION
(2012)
Article
Oncology
Nora M. Barboza, Daniel J. Medina, Tulin Budak-Alpdogan, Miguel Aracil, Jose M. Jimeno, Joseph R. Bertino, Debabrata Banerjee
CANCER BIOLOGY & THERAPY
(2012)
Article
Oncology
Sonia C. Dolfi, Adriana V. Jaeger, Daniel J. Medina, Bruce G. Haffty, Jin-Ming Yang, Kim M. Hirshfield
Article
Oncology
Tulin Budak-Alpdogan, Bobin Chen, Aniali Warrier, Daniel J. Medina, Dirk Moore, Joseph R. Bertino
CLINICAL CANCER RESEARCH
(2009)
Article
Hematology
Dale G. Schaar, Daniel J. Medina, Dirk F. Moore, Roger K. Strair, Y. Ting
EXPERIMENTAL HEMATOLOGY
(2009)
Article
Hematology
Daniel J. Medina, Lauri Goodell, John Glod, Celine Gelinas, Arnold B. Rabson, Roger K. Strair
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
(2012)
Article
Multidisciplinary Sciences
Daniel J. Medina, Jeneba Abass-Shereef, Kelly Walton, Lauri Goodell, Hana Aviv, Roger K. Strair, Tulin Budak-Alpdogan
Article
Oncology
Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2019)
Article
Multidisciplinary Sciences
Jenna H. Newman, C. Brent Chesson, Nora L. Herzog, Praveen K. Bommareddy, Salvatore M. Aspromonte, Russell Pepe, Ricardo Estupinian, Mones M. Aboelatta, Stuti Buddhadev, Saeed Tarabichi, Michael Lee, Shengguo Li, Daniel J. Medina, Eileena F. Giurini, Kajal H. Gupta, Gabriel Guevara-Aleman, Marco Rossi, Christina Nowicki, Abdulkareem Abed, Josef W. Goldufsky, Joseph R. Broucek, Raquel E. Redondo, David Rotter, Sachin R. Jhawar, Shang-Jui Wang, Frederick J. Kohlhapp, Howard L. Kaufman, Paul G. Thomas, Vineet Gupta, Timothy M. Kuzel, Jochen Reiser, Joyce Paras, Michael P. Kane, Eric A. Singer, Jyoti Malhotra, Lisa K. Denzin, Derek B. Sant'Angelo, Arnold B. Rabson, Leonard Y. Lee, Ahmed Lasfar, John Langenfeld, Jason M. Schenkel, Mary Jo Fidler, Emily S. Ruiz, Amanda L. Marzo, Jai S. Rudra, Ann W. Silk, Andrew Zloza
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Urology & Nephrology
Aparna Kareddula, Daniel J. Medina, Whitney Petrosky, Sonia Dolfi, Irina Tereshchenko, Kelly Walton, Hana Aviv, Evita Sadimin, Alexandra L. Tabakin, Eric A. Singer, Kim M. Hirshfield
Summary: The study found that deletion of CHD1 in low-grade prostate cancer leads to changes in cell morphology, reduced adhesion strength, and altered expression of extracellular matrix and adhesion molecules. These results highlight the crucial role of CHD1 in the development and progression of PCa.
THERAPEUTIC ADVANCES IN UROLOGY
(2021)
